Are we making progress in kidney transplantation?

Current Opinion in Organ Transplantation

Volumn 11, Issue 1, 2006, Pages 1-6

  Mekeel, Kristin ^a   Meier Kriesche, Herwig Ulf ^a   Kaplan, Bruce ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Box 100224 ^*  (United States)

Author keywords

Acute rejection; Graft survival; Kidney transplant

Indexed keywords

CYCLOSPORIN; FLUINDOSTATIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; RAPAMYCIN;

CLINICAL TRIAL; DATA ANALYSIS; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; QUALITY OF LIFE; RENAL GRAFT DYSFUNCTION; REVIEW; TREATMENT OUTCOME;

EID: 33644632718     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000203881.02687.51     Document Type: Review

References (54)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
2. Doyle AM, Lechler RI, Turka LA. Organ transplantation: halfway through the first century. J Am Soc Nephrol 2004; 15:2965-2971. This review article concentrates on the early history of renal transplantation.
3. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises. N Engl J Med 2004; 351:2761-2766. This is another review article, which places greater emphasis on chronic allograft dysfunction and immunology.
4. Merion RM, White DJ, Thiru S, et al. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310:148-154.
5. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U. S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225-232.
6. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977-983.
7. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3 (suppl 2):1-5.
8. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-383. This study of the Scientific Registry of Transplant Recipients database shows the lack of impact on long-term graft survival despite improvements in acute rejection.
9. Tesi RJ, Elkhammas EA, Henry ML, et al. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993; 25:901-902.
10. Pirsch JD, Ploeg RJ, Gange S, et al. Determinants of graft survival after renal transplantation. Transplantation 1996; 61:1581-1586.
11. Almond PS, Matas AJ, Gillingham K, et al. Predictors of chronic rejection in renal transplant recipients. Transplant Proc 1993; 25:936.
12. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8:328-331.
13. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996; 62:1235-1241.
14. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342:605-612.
15. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4:1289-1295. This study demonstrates little improvement in long-term graft survival from 1988 to 1995, despite more optimistic previous projections.
16. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13:769-772.
17. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2:970-974.
18. Knoll G, Muirhead N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5:1719-1724. This report confirms the US experience demonstrating a high mortality when patients return to dialysis after renal transplantation.
19. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291-1295.
20. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662-1668. This epidemiologic study demonstrates an increased risk for cardiac death in patients on hemodialysis, which is halted by renal transplantation.
21. Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005; 5:1405-1414. This five-center collaborative study indicates that the slope of creatinine clearance may be improving in the most recent era.
22. Gourishankar S, Hunsicker LG, Jhangri GS, et al. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003; 14:2387-2394.
23. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62:311-318.
24. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003; 3:1560-1565.
25. Hariharan S, Kasiske B, Matas A, et al. Surrogate markers for long-term renal allograft survival. Am J Transplant 2004; 4:1179-1183. A comprehensive review of surrogate markers for long-term graft survival is presented.
26. Pape L, Henne T, Offner G, et al. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003; 76:955-958.
27. Grimm PC. Novel methods of prediction of long-term renal allograft outcome. Pediatr Transplant 2004; 8:531-532. This is a review of possible surrogate markers for graft loss.
28. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18:22-28. This prospective randomized trial shows improved long-term graft survival in patients who undergo early calcineurin inhibitor withdrawal.
29. Madden RL, Mulhern JG, Benedetto BJ, et al. Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transpl Int 2000; 13:344-350.
30. Vereerstraeten P, Abramowicz D, de Pauw L, et al. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63:1739-1743.
31. He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc 2004; 36:2993-2996. This retrospective study of more than 1700 patients found rejection less than 3 months after transplant was not associated with an increased risk for chronic allograft nephropathy, but acute rejection over 1 year after transplant was associated with chronic allograft nephropathy.
32. Fabrizii V, Winkelmayer WC, Klauser R, et al. Patient and graft survival in older kidney transplant recipients: does age matter? J Am Soc Nephrol 2004; 15:1052-1060. This retrospective study looked at 5-year graft survival based on recipient age, finding that graft survival was not significantly different in patients older than 60 years.
33. Meier-Kriesche HU, Srinivas TR, Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplant Proc 2001; 33:3425-3426.
34. Meier-Kriesche HU, Schold JD, Gaston RS, et al. Kidneys from deceased donors: maximizing the value of a scarce resource. Am J Transplant 2005; 5:1725-1730. This retrospective study looked at kidneys from young donors placed into older recipients, showing an estimated loss of 27 500 graft years secondary to the early death of older patients with functioning grafts from young donors.
35. Buehrig CK, Lager DJ, Stegall MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64:665-673.
36. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79:1277-1286.
37. Wali RK, Drachenberg C, Hirsch HH, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004; 78:1069-1073.
38. Lipshutz GS, Flechner SM, Govani MV, et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4:2132-2134.
39. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352:1157-1158.
40. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55:674-685.
41. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the 'creeping creatinine' study. Transplantation 2005; 79:466-475. This is an important study of patients with chronic allograft nephropathy in which the withdrawal of calcineurin inhibitors with mycophenolate mofetil as a substitute resulted in improvement in renal function.
42. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5:1748-1756. This meta-analysis of the literature on calcineurin inhibitor withdrawal with sirolimus replacement in patients with chronic allograft nephropathy demonstrated an increase in acute rejection but improvements in renal function and hypertension.
43. Melk A, Halloran PF. Cell senescence and its implications for nephrology. J Am Soc Nephrol 2001; 12:385-393.
44. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69:319-326.
45. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: post-transplant analysis using flow cytometric techniques. Transplantation 2001; 71:1106-1112.
46. Joosten SA, van Kooten C, Sijpkens YW, et al. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int 2004; 65:1556-1559. This review covers antibody mediated long-term immunologic injury and graft senescence.
47. Cosio FG, Kudva Y, Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67:2415-2421.
48. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185.
49. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53:217-222.
50. Cosio FG, Pelletier RP, Sedmak DD, et al. Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 1999; 56:1912-1919.
51. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61:1469-1474.
52. Kasiske B. Managing dyslipidemias in chronic kidney disease. Nephrol News Issues 2003; 17:81-83; 93.
53. Holdaas H, Julian D. The use of statins after solid organ transplantation [letter]. Nephrol Dial Transplant 2002; 17:1537.
54. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024-2031.